Multimodal Assessment of Cognitive Impairment in Alzheimer Patients
Overview
- Phase
- N/A
- Intervention
- 64-channel EEG
- Conditions
- Mild Cognitive Impairment
- Sponsor
- Norwegian University of Science and Technology
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- AD-subclassification
- Status
- Recruiting
- Last Updated
- 8 months ago
Overview
Brief Summary
The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD).
The main questions the study aims to answer are:
- What findings can be used to earlier detect patients that will develop Alzheimers?
- Which differences are seen between healthy and cognitively impaired patients?
- Which differences are seen between patients with Alzheimers disease?
Participants will undergo:
- Cognitive tests
- Magnetic resonance imaging (MRI)
- Electroencephalography (EEG)
- Blood sample collection
- Fecal sample collection
- A randomized group will undergo polysomnography analysis.
Detailed Description
The projects aims to map brain changes in patients with mild cognitive impairment (MCI) and Alzheimer's Disease (AD) by combining different assesment modalities. In the MRI, researchers will get the opportunity to analyse both structural and functional brain changes. In the EEG, changes in elctrical activites will be measured. The blood samples allow researchers to analyse specific dementia and inflammation proteins, while fecal speciments can be used to assess bacterial composition. Additionally, the cognitive testing allow to assess the specific part of cognitive function which is affected.
Investigators
Eligibility Criteria
Inclusion Criteria
- •MCI and AD according to relevant ICD-criterias.
- •Control cohort is age and gender matched with other cohorts.
Exclusion Criteria
- •Uneligibility for any of the planned neuroimagery devices (MRI, EEG)
- •AD diagnosis before the age of 65 (Early-onset AD).
- •Brain tumor
- •Traumtic head injury
- •Earlier neurosurgery
- •Other neyrodegenerative diseases (i.e Parkinson and ALS)
- •Diseases related to inflammation and auto-immunity (i.e MS)
Arms & Interventions
MCI
Recruitment according to relevant clinical assessment and ICD-criterias.
Intervention: 64-channel EEG
MCI
Recruitment according to relevant clinical assessment and ICD-criterias.
Intervention: Polysomnography
MCI
Recruitment according to relevant clinical assessment and ICD-criterias.
Intervention: Blood samples
MCI
Recruitment according to relevant clinical assessment and ICD-criterias.
Intervention: Fecal samples
MCI
Recruitment according to relevant clinical assessment and ICD-criterias.
Intervention: MRI Scanning
MCI
Recruitment according to relevant clinical assessment and ICD-criterias.
Intervention: Cognitive tests
Mild AD
Recruitment according to relevant clinical assessment and ICD-criterias.
Intervention: MRI Scanning
Mild AD
Recruitment according to relevant clinical assessment and ICD-criterias.
Intervention: 64-channel EEG
Mild AD
Recruitment according to relevant clinical assessment and ICD-criterias.
Intervention: Polysomnography
Mild AD
Recruitment according to relevant clinical assessment and ICD-criterias.
Intervention: Blood samples
Mild AD
Recruitment according to relevant clinical assessment and ICD-criterias.
Intervention: Fecal samples
Mild AD
Recruitment according to relevant clinical assessment and ICD-criterias.
Intervention: Cognitive tests
Control
Equivalent number of research participants as in the MCI and mild AD group.
Intervention: MRI Scanning
Control
Equivalent number of research participants as in the MCI and mild AD group.
Intervention: 64-channel EEG
Control
Equivalent number of research participants as in the MCI and mild AD group.
Intervention: Polysomnography
Control
Equivalent number of research participants as in the MCI and mild AD group.
Intervention: Blood samples
Control
Equivalent number of research participants as in the MCI and mild AD group.
Intervention: Fecal samples
Control
Equivalent number of research participants as in the MCI and mild AD group.
Intervention: Cognitive tests
Outcomes
Primary Outcomes
AD-subclassification
Time Frame: 5 years
Identify biomarker profiles that can assist in a more thorough AD-classification
MCI-AD converters
Time Frame: 5 years
Identify biomarker profiles unique for patients with MCI that develop AD for earlier prediction.